<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933162</url>
  </required_header>
  <id_info>
    <org_study_id>20-012389</org_study_id>
    <nct_id>NCT04933162</nct_id>
  </id_info>
  <brief_title>UC Cohort - The Influence of Diet on Gut Microbiotas</brief_title>
  <official_title>UC Cohort - The Influence of Diet on Host Physiology and Disease Across Diverse Human Gut Microbiotas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine if different diets have different effects on the&#xD;
      inflammation in the colon.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in endoscopic Mayo score for ulcerative colitis inflammation</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured from unprepped, non-sedated flexible sigmoidoscopy by decrease in Mayo score with a decrease of at least 1 point on the endoscopic subscore or absolute endoscopic subscore of 0-1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical remission derived from patient reported outcomes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Defined as a Mayo score ≤2 and no sub-scores with a value greater than 1 is a secondary endpoint. This what the patient reports for stool frequency and reporting of any blood in the stool</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intestinal inflammation determined from blood and stool samples</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measures C-reactive protein from blood samples and fecal calprotectin from stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of lactulose and 13C-Mannitol</measure>
    <time_frame>8 weeks</time_frame>
    <description>Small Bowel and Colonic Permeability by Urinary Excretion of Lactulose and 13C-Mannitol after Oral Ingestion of lactulose and 13C mannitol (5:1 ratio by mass). The 0-2h urine most closely reflects small intestinal permeability and 8-24h urine reflects colonic permeability. HPLC-tandem mass spectrometry will be used for detection of the sugars. The results will be expressed as the ratio of percentage excretion of the ingested dose of lactulose and mannitol in urine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>High Protein and Low Fiber Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume a high protein and low fiber diet for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Protein and High Fiber Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume a low protein and high fiber diet for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High Protein and Low Fiber Diet</intervention_name>
    <description>Protein intake will be increased to be &gt;40% calories from protein, and the fiber intake will remain &lt;15gm/day.</description>
    <arm_group_label>High Protein and Low Fiber Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low Protein and High Fiber Diet</intervention_name>
    <description>Increase fiber intake up to 40gms of fiber with a requirement to increase at least 15gms above baseline fiber, with 50-75% of total fiber intake from psyllium husk. Subjects will be allowed to slowly increase fiber every two days to reach goal by end of week 1. The total protein will be reduced to &lt;10% total calories from protein.</description>
    <arm_group_label>Low Protein and High Fiber Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults ≥ 18 years old&#xD;
&#xD;
          2. Ability to give informed consent&#xD;
&#xD;
          3. Diagnosis of ulcerative colitis&#xD;
&#xD;
          4. Moderate UC disease activity defined by a Mayo Score of &gt;6 with endoscopic score of 2&#xD;
&#xD;
          5. On a baseline diet characterized by:&#xD;
&#xD;
               -  Fiber intake of &lt; 15g/day&#xD;
&#xD;
               -  &gt; 18% of daily calories from protein&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior history of gastrointestinal surgeries (except appendectomy and cholecystectomy)&#xD;
&#xD;
          2. Use of tobacco products within the past 6 months (since nicotine may affect intestinal&#xD;
             permeability)&#xD;
&#xD;
          3. Use of NSAIDs or aspirin and unable or unwilling to stop taking two weeks prior to&#xD;
             permeability test and for the duration of the study&#xD;
&#xD;
          4. Use of osmotic laxatives and unable or unwilling to stop taking one week prior to&#xD;
             permeability test and for the duration of the study&#xD;
&#xD;
          5. Use of oral corticosteroids and unable or unwilling to stop use of oral&#xD;
             corticosteroids within the previous 2 weeks and for the duration of the study&#xD;
&#xD;
          6. Multiple dietary restrictions or unable/unwilling to alter dietary protein or dietary&#xD;
             fiber.&#xD;
&#xD;
          7. Unwilling to stop ingestion of alcohol and artificial sweeteners such as Splenda™&#xD;
             (sucralose), Nutrasweet™ (aspartame), sorbitol, xylitol, lactulose, or mannitol 2 days&#xD;
             before and during the permeability testing days, e.g. foods to be avoided are&#xD;
             sugarless gums or mints and diet beverages&#xD;
&#xD;
          8. Unwilling to stop stenuous exercise (running &gt;5 miles or equivalent) one week prior to&#xD;
             the permeability tests&#xD;
&#xD;
          9. Bowel preparation for colonoscopy less than one week prior to completion of the first&#xD;
             stool kit and permeability test and flexible sigmoidoscopy and upper endoscopy&#xD;
&#xD;
         10. Pregnancy or plan to become pregnant during the study time frame&#xD;
&#xD;
         11. Vulnerable adult&#xD;
&#xD;
         12. Known bleeding disorders or takes medications that increase risk of bleeding from&#xD;
             mucosal biopsies&#xD;
&#xD;
         13. Use of oral antibiotic(s) within the past 4 weeks (can be enrolled after 4-week&#xD;
             washout period)&#xD;
&#xD;
         14. Use of commercial probiotic formulations and unwilling to stop for the duration of the&#xD;
             study&#xD;
&#xD;
         15. Diagnosis of diabetes&#xD;
&#xD;
         16. Any other disease(s), condition(s) or habits(s) that would interfere with completion&#xD;
             of study, or in the judgment of the investigator would potentially interfere with&#xD;
             compliance to this study or would adversely affect study outcomes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Raffals, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chad Rypstra</last_name>
    <phone>(507) 538-4298</phone>
    <email>rypstra.chad@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chad Rypstra</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Laura E. Raffals, M.D</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

